Patients must have follicular lymphoma (grade I, II or IIIa) confirmed at initial diagnosis and at relapse with identifiable fludeoxyglucose F-18 (FDG) avid disease on PET/CT; patients that have involvement with large cell lymphoma are not eligible
Systemic lymphoma
Fluorodeoxyglucose (FDG)-avid lymphoma (that is [i.e.], PET-positive lymphoma)
Histologically confirmed, relapsed or refractory, follicular B-cell NHL (follicular lymphoma) Grade 1, 2, and 3a.
Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.
Grade 3b follicular lymphoma
One of the following untreated, histological confirmed lymphoma expressing cluster of differentiation (CD)20 antigen\r\n* DLBCL with disconcordant and/or composite pathology e.g. low grade follicular lymphoma within bone marrow or lymph node are eligible\r\n* DLBCL transformation follicular lymphoma (FL) – untreated with anthracyclines or high dose chemotherapy/autologous stem cell transplantation; patients treated with rituximab alone, non-anthracycline containing regiments and previously observed only are eligible
Non-Hodgkin’s lymphoma (NHL) or Hodgkin’s lymphoma (HL) beyond first remission
All risk by Follicular Lymphoma International Prognostic Index (FLIPI) 0-5 factors
Burkitt lymphoma
lymphoma
Adults with histologically proven solid malignancy, high-grade lymphoma or low-grade lymphoma
Transformed lymphoma
Patients with indolent non-Hodgkin lymphoma (NHL) must have had >= 1 regimen of rituximab-containing regimen; Note: this includes follicular lymphoma (FL), marginal lymphoma and mucosa-associated lymphoid tissue (MALT)
History of indolent lymphoma
History of follicular lymphoma grade 3B
Burkitt lymphoma
Refractory to chemotherapy lymphoma
Patients with indolent lymphoma must have an indication for treatment in the opinion of the investigator
Follicular Lymphoma I, II, IIIA
Lymphoplasmocytic lymphoma
Measurable or assessable lymphoma
Patients with a low grade lymphoma or CLL and a concurrent high grade lymphoma transformed from the low grade lymphoma or CLL will be eligible
Transformation to high-grade lymphoma secondary to previously untreated low-grade lymphoma.
No prior treatment for lymphoma
Follicular lymphoma G1-2-3a
Previously untreated diffuse large B-cell lymphoma or grade 3B follicular lymphoma (of any stage); subjects must be planned to receive full course (6 cycles) of RCHOP chemoimmunotherapy as per clinical standard of care; patients may have de novo DLBCL, and /or any of the following:\r\n* Composite lymphomas, which include both diffuse DLBCL and another histology (most commonly follicular lymphoma) in the same lymph node\r\n* Transformed lymphoma with DLBCL histology, as long as the patient has not received prior therapy for lymphoma\r\n* Discordant presentations, such as DLBCL in a lymph node  and low-grade lymphoma such as follicular lymphoma in the bone marrow
Histologies of myeloma or lymphoma
Only 1 line of previous anti-lymphoma therapy is allowed and not currently receiving any other agent that would be considered as a treatment for the lymphoma; patients must be >= 2 weeks from prior anti-lymphoma therapy; the use of steroids and/or rituximab up to 1 week prior to registration for management of symptoms is allowed
All cancer diagnoses, except lymphoma, will be eligible
Diagnosis of lymphoma
Inclusion Criteria:\n\n        -- Age ?18 years\n\n          -  Histologically confirmed Follicular Lymphoma (Grade 1, 2 or 3a), Marginal Zone\n             Lymphoma, or Mantle Cell Lymphoma\n\n          -  Must have documented relapsed, refractory or Progressive Disease after last treatment\n             with systemic therapy\n\n          -  Bi-dimensionally measurable disease\n\n          -  Eastern Cooperative Oncology Group (ECOG) Performance status ? 2\n\n          -  Adequate bone marrow function\n\n          -  Willingness to follow pregnancy precautions\n\n        Exclusion Criteria:\n\n          -  Histology other than follicular or marginal zone lymphoma or clinical evidence of\n             transformation or Grade 3b follicular lymphoma\n\n          -  Any medical condition (other than the underlying lymphoma) that requires chronic\n             steroid use\n\n          -  Subjects taking corticosteroids during the last 1 week prior treatment, unless\n             administered at a dose equivalent to < 20 mg/day of prednisone\n\n          -  Systemic anti-lymphoma therapy within 28 days or use of antibody agents within 8 weeks\n             use of radioimmunotherapy within 3 months\n\n          -  Known seropositive for or active viral infection with hepatitis B virus (HBV),\n             hepatitis C virus (HCV), human immunodeficiency virus (HIV)\n\n          -  Known sensitivity or allergy to murine products\n\n          -  Presence or history of central nervous system involvement by lymphoma. Subjects who\n             are at a risk for a thromboembolic event and are not willing to take prophylaxis for\n             it.\n\n          -  Any condition that places the subject at unacceptable risk if he/she were to\n             participate in the study or that confounds the ability to interpret data from the\n             study.
Known secondary HPS that is otherwise treatable (e.g. non-Hodgkin’s lymphoma)
Follicular lymphoma(FL) grade1-2-3a
Patients will be ineligible if they have a lymphoma diagnosis
Lymphoma\r\n* Relapsed lymphoma with residual disease that appears to be chemo-sensitive and non-bulky (< 5 cm at largest diameter)
Absolute neutrophil count (ANC) > 1000 unless impairment is due to lymphoma or immune-mediated mechanism caused by lymphoma
Platelets > 100,000 unless impairment is due to lymphoma or immune-mediated mechanism caused by lymphoma
Histologically confirmed diagnosis of B-cell follicular lymphoma (FL), and grade limited to 1, 2, or 3a based on criteria established by the WHO 2008 classification of tumors of hematopoietic and lymphoid tissues
Confirmed diagnosis of low tumour burden, CD20+ follicular lymphoma
Histologically confirmed follicular lymphoma, grade 1-3a.
Prior chemotherapy for lymphoma
Previous history of indolent lymphoma treated with more than 1 multi-agent chemotherapy regimen or previous cancer therapy for recurrent DLBCL or Grade 3b follicular lymphoma
Known central nervous system lymphoma, leptomeningeal lymphoma, or histologic evidence of transformation from an indolent lymphoma to a high-grade or DLBCL
Treatment-naive patients with histologically confirmed systemic de novo or transformed diffuse large B-cell lymphoma (DLBCL) (from follicular or marginal zone lymphoma), or follicular lymphoma (FL) Grade 3b;
Previous history of treated indolent lymphoma
Fluorodeoxyglucose-avid lymphoma (i.e., PET-positive lymphoma)
Grade 3b follicular lymphoma
Any prior treatment for non-Hodgkin’s lymphoma
A diagnosis of follicular lymphoma (grades 1, 2, or 3a), untreated
Grade 3b follicular lymphoma
Fluorodeoxyglucose-avid lymphoma
Patients with follicular lymphoma must have received at least two prior therapies
Patients with histologically confirmed aggressive hematologic malignancies with chemotherapy-refractory disease; chemotherapy refractory disease is defined as one or more of the following: stable disease or progressive disease as best response to most recent chemotherapy containing regimen or disease progression or recurrence within 12 months of prior autologous or allogeneic stem cell transplant; subjects must have received adequate prior therapy including at a minimum: anti-cluster of differentiation (CD)20 monoclonal antibody unless tumor is CD20-negative, an anthracycline containing chemotherapy regimen; subjects with transformed follicular lymphoma (FL) must have received prior chemotherapy for follicular lymphoma and subsequently have chemo-refractory disease after transformation to diffuse large B-cell lymphoma (DLBCL)
Participants with transformed lymphoma
Histology other than follicular or marginal zone lymphoma or clinical evidence of transformation or Grade 3b follicular lymphoma.
Platelets >= 100 x 10^9/L or >= 50 x 10^9/L (if related to lymphoma)
No prior anti-lymphoma treatment.
Composite lymphoma or transformed lymphoma.
Histologically documented CD20-positive lymphoma and fluorodeoxyglucose (FDG)-avid lymphoma (that is PET-positive lymphoma) with at least one bi-dimensionally measurable lesion
Grade 3b follicular lymphoma
Have had no prior systemic treatment for lymphoma
Follicular lymphoma (FL) grade 1-2-3a.
Histologically confirmed diagnosis of B-cell indolent Non-Hodgkin lymphoma with histological subtype limited to follicular lymphoma or marginal zone lymphoma, at initial diagnosis and without evidence of pathological transformation or clinical signs suggesting transformation
Diagnosis of lymphoma
Prior history of indolent lymphoma
Follicular lymphoma (FL) grade 1-2-3a
Histologically confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV
Have no prior systemic treatment for lymphoma
Symptomatic follicular lymphoma requiring treatment.
Clinical evidence of transformed lymphoma or Grade 3b follicular lymphoma.
For participants with follicular lymphoma: requirement for treatment according to Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria
Grade 3b follicular lymphoma, small lymphocytic lymphoma or Waldenström's macroglobulinaemia
For participants with follicular lymphoma: prior treatment for non-Hodgkin's lymphoma with chemotherapy, immunotherapy, or radiotherapy
For participants with non-follicular lymphoma: prior treatment with chemotherapy or immunotherapy
Patient has histologically confirmed diagnosis of follicular lymphoma or Hodgkin lymphoma
More than one prior line of any systemic chemoimmunotherapy for follicular lymphoma
Transformed lymphoma
Prior treatment for follicular lymphoma
Grade 3b follicular lymphoma or evidence that the indolent lymphoma has transformed to aggressive lymphoma
For patients with non-Hodgkin’s lymphoma, they must be determined to have at least stable disease to last therapy
TIER I SUBJECTS: Histologically confirmed follicular lymphoma (grade 1, 2 or 3) by the World Health Organization (WHO) classification; all pathology must be confirmed at either Brigham and Women's Hospital or Massachusetts General Hospital; a repeat biopsy confirming the above histologies must be performed prior to enrollment if there is clinical suspicion that the patient has transformed to a more aggressive lymphoma
TIER II SUBJECTS: Histologically confirmed follicular lymphoma (grade 1, 2 or 3) by the WHO classification; all pathology must be confirmed at either Brigham and Women's Hospital or Massachusetts General Hospital; a repeat biopsy confirming the above histologies must be performed prior to enrollment if there is clinical suspicion that the patient has transformed to a more aggressive lymphoma
Lymphoma accessible for sampling or existing cryopreserved lymphoma tumor judged suitable for preparation of vaccine
Any component of transformed follicular lymphoma
Follicular lymphoma (FL) Grade 1, 2, or 3a
Previous history of treated indolent lymphoma
Transformation Follicular Lymphoma (TFL)
Confirmed diagnosis of low tumor burden, CD20-positive follicular lymphoma
Follicular lymphoma (FL)
Diagnosis of CD20+, follicular lymphoma that has not been treated
CD20-immunophenotyping of tumor to document B-cell follicular lymphoma
Clinical evidence of transformation to a more aggressive subtype of lymphoma or grade 3B follicular lymphoma
Participants must have histologically confirmed follicular lymphoma (FL) of Grade 1, 2, or 3a
Has enlarged lymph node(s) highly suspicious of lymphoma; or has been diagnosed with lymphoma but is untreated; or has persistent recurrent, or progressive lymphoma
Pathologically confirmed diagnosis of mantle cell lymphoma, follicular lymphoma Grade 3, diffuse large B-cell lymphoma (DLBCL), including transformed follicular histology, Burkitt lymphoma, or B-lineage lymphoblastic lymphoma
Follicular Lymphoma (FL) must have at least 1 lesion that can be biopsied at screening and on treatment
Prior therapy for lymphoma
Follicular lymphoma Grades 1, 2, 3 A
Lymphoplasmacytic lymphoma
One or more of the following lymphoma-related symptoms:
presence of lymphoma-related complications, including narrowing of ureters or bile ducts, tumor-related compression of a vital organ, lymphoma-induced pain, cytopenias related to lymphoma/leukemia, splenomegaly, pleural effusions, or ascites
Corticosteroids for treatment of lymphoma within 28 days of study entry Chronically administered low-dose corticosteroids (e.g., prednisone ?20 mg/day) for indications other than lymphoma or lymphoma-related complications are permitted
Inclusion Criteria:\n\n          1. Previously untreated stage IV indolent B-cell lymphoma [Amendment May 2001:\n             eligibility restricted to follicular lymphoma]\n\n          2. Age <76\n\n        Exclusion Criteria:
No prior chemotherapy for lymphoma
Patients with follicular, grade 1 or 2 non-Hodgkin lymphoma with a FLIPI (Follicular Lymphoma International Prognostic Index) score of 0-2, with no anticipated need for treatment within the next 5 months are considered eligible for this study, regardless of previous treatment history
Survivors of mediastinal lymphoma (either non-Hodgkin’s lymphoma or Hodgkin’s lymphoma) with no active malignancy
Histologies of myeloma or lymphoma
Patients with transformed lymphoma (e.g., Richter's transformation arising in follicular lymphoma or chronic lymphocytic leukemia)
Follicular lymphoma Grade 3B
Patients with transformed lymphoma (e.g., Richter's transformation arising in follicular lymphoma or chronic lymphocytic leukemia)
Patients with transformed lymphoma (e.g., Richters transformation arising in follicular lymphoma or chronic lymphocytic leukemia)
History of lymphoma
Follicular variant